Back to Newsroom
Back to Newsroom

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of STAA, VXRT and ACB

Thursday, 08 October 2020 04:25 PM

The Gross Law Firm

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / October 8, 2020 /The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Staar Surgical Company (NASDAQ:STAA)

Investors Affected: February 26, 2020 - August 10, 2020

A class action has commenced on behalf of certain shareholders in Staar Surgical Company. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the Company was overstating and/or mischaracterizing: (1) its sales and growth in China; (2) its marketing spend; (3) its research and development expenses; and that as a result of the foregoing, (4) Defendants' public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/staar-surgical-company-loss-submission-form/?id=9933&from=1

Vaxart, Inc. (NASDAQ:VXRT)

Investors Affected: June 25, 2020 - July 25, 2020

A class action has commenced on behalf of certain shareholders in Vaxart, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) Vaxart exaggerated the prospects of its COVID-19 vaccine candidate, including its purported role or involvement in Operation Warp Speed ('OWS'), a program which commits the federal government to massive funding for the development of COVID-19 vaccines; 2) Vaxart's COVID-19 vaccine candidate had no reasonable prospect for mass production and marketing and was not among the companies chosen to receive significant financial support from OWS to produce hundreds of millions of vaccine doses; and 3) Vaxart's COVID-19 vaccine candidate was merely selected to participate in preliminary U.S. government studies to determine potential areas for possible OWS partnership and support.

Shareholders may find more information at https://securitiesclasslaw.com/securities/vaxart-inc-loss-submission-form/?id=9933&from=1

Aurora Cannabis Inc. (NYSE:ACB)

Investors Affected: February 13, 2020 - September 4, 2020

A class action has commenced on behalf of certain shareholders in Aurora Cannabis Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (ii) the Company's purported "business transformation plan" and cost reset failed to mitigate the foregoing issues; (iii) accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/aurora-cannabis-inc-loss-submission-form-2/?id=9933&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: